Novavax Covid-19 Vaccine Gets Health Canada Approval for Adolescents


By Adriano Marchese

Novavax Inc. said Wednesday that Canada’s health regulator has approved its Covid-19 vaccine in adolescents aged 12 through 17.

The vaccine developer said that Health Canada approved its supplement to a new drug submission for Nuvaxovid which works towards immunization to help prevent the coronavirus in individuals.

The approval was based on data from pediatric expansion of the phase 3 trial in the U.S. which has showed that effectiveness was higher in adolescents than in young adults.

Trials have found that protective efficacy was of 79.5% overall at a time when the Delta variant was the predominant circulating strain.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

12-07-22 1018ET



Source link

Ozinize
Logo
Shopping cart